BNP Paribas Financial Markets’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28M | Buy |
490,189
+41,421
| +9% | +$2.27M | 0.01% | 1063 |
|
|
2026
Q1 | $25.4M | Buy |
448,768
+12,744
| +3% | +$743K | 0.01% | 1010 |
|
|
2025
Q4 | $25.9M | Buy |
436,024
+81,335
| +23% | +$4.43M | 0.01% | 1031 |
|
|
2025
Q3 | $19.2M | Buy |
354,689
+11,410
| +3% | +$653K | 0.01% | 1140 |
|
|
2025
Q2 | $18.9M | Buy |
343,279
+212,502
| +162% | +$12.5M | 0.01% | 1074 |
|
|
2025
Q1 | $9.24M | Sell |
130,777
-16,360
| -11% | -$1.1M | 0.01% | 1447 |
|
|
2024
Q4 | $9.67M | Sell |
147,137
-3,227
| -2% | -$216K | 0.01% | 1380 |
|
|
2024
Q3 | $10.6M | Buy |
150,364
+17,010
| +13% | +$1.42M | 0.01% | 1144 |
|
|
2024
Q2 | $11M | Sell |
133,354
-79,083
| -37% | -$6.58M | 0.01% | 1052 |
|
|
2024
Q1 | $18.6M | Sell |
212,437
-127,794
| -38% | -$11.4M | 0.02% | 816 |
|
|
2023
Q4 | $32.8M | Buy |
340,231
+162,768
| +92% | +$14.4M | 0.04% | 502 |
|
|
2023
Q3 | $15.7M | Sell |
177,463
-48,644
| -22% | -$4.33M | 0.02% | 707 |
|
|
2023
Q2 | $19.6M | Sell |
226,107
-14,260
| -6% | -$1.34M | 0.02% | 622 |
|
|
2023
Q1 | $23.4M | Buy |
240,367
+8,530
| +4% | +$884K | 0.03% | 527 |
|
|
2022
Q4 | $24M | Buy |
+231,837
| New | +$21.8M | 0.04% | 580 |
|
|
2022
Q3 | – | Sell |
-195,856
| Closed | -$16.2M | – | 4761 |
|
|
2022
Q2 | $16.2M | Buy |
195,856
+7,868
| +4% | +$626K | 0.03% | 675 |
|
|
2022
Q1 | $14.5M | Buy |
187,988
+54,556
| +41% | +$4.56M | 0.02% | 740 |
|
|
2021
Q4 | $11.8M | Buy |
133,432
+59,621
| +81% | +$4.92M | 0.02% | 882 |
|
|
2021
Q3 | $5.7M | Buy |
73,811
+10,192
| +16% | +$804K | 0.01% | 1227 |
|
|
2021
Q2 | $5.31M | Sell |
63,619
-9,184
| -13% | -$728K | 0.01% | 1252 |
|
|
2021
Q1 | $5.5M | Sell |
72,803
-74,414
| -51% | -$6.08M | 0.01% | 1120 |
|
|
2020
Q4 | $12.9M | Sell |
147,217
-22,666
| -13% | -$1.8M | 0.02% | 676 |
|
|
2020
Q3 | $12.9M | Sell |
169,883
-45,435
| -21% | -$4.6M | 0.02% | 672 |
|
|
2020
Q2 | $26.6M | Buy |
215,318
+69,490
| +48% | +$6.91M | 0.05% | 364 |
|
|
2020
Q1 | $12.3M | Sell |
145,828
-22,257
| -13% | -$1.92M | 0.03% | 583 |
|
|
2019
Q4 | $14.2M | Buy |
168,085
+67,919
| +68% | +$5.13M | 0.03% | 646 |
|
|
2019
Q3 | $6.75M | Sell |
100,166
-47,949
| -32% | -$3.69M | 0.01% | 940 |
|
|
2019
Q2 | $12.7M | Buy |
148,115
+63,259
| +75% | +$5.41M | 0.03% | 622 |
|
|
2019
Q1 | $7.54M | Buy |
84,856
+40,187
| +90% | +$3.72M | 0.02% | 810 |
|
|
2018
Q4 | $3.8M | Sell |
44,669
-105,895
| -70% | -$10.1M | 0.01% | 1034 |
|
|
2018
Q3 | $14.6M | Buy |
150,564
+67,495
| +81% | +$6.74M | 0.02% | 663 |
|
|
2018
Q2 | $7.83M | Sell |
83,069
-13,953
| -14% | -$1.22M | 0.01% | 898 |
|
|
2018
Q1 | $7.87M | Buy |
97,022
+20,242
| +26% | +$1.74M | 0.01% | 797 |
|
|
2017
Q4 | $6.85M | Buy |
76,780
+21,259
| +38% | +$1.85M | 0.01% | 900 |
|
|
2017
Q3 | $5.17M | Buy |
55,521
+34,430
| +163% | +$3.04M | 0.01% | 789 |
|
|
2017
Q2 | $1.92M | Sell |
21,091
-25,625
| -55% | -$2.33M | 0.01% | 1202 |
|
|
2017
Q1 | $4.1M | Buy |
46,716
+13,051
| +39% | +$1.16M | 0.01% | 823 |
|
|
2016
Q4 | $2.79M | Sell |
33,665
-66,083
| -66% | -$5.68M | 0.01% | 799 |
|
|
2016
Q3 | $9.23M | Buy |
99,748
+76,885
| +336% | +$7.24M | 0.04% | 315 |
|
|
2016
Q2 | $1.78M | Sell |
22,863
-33,607
| -60% | -$2.86M | 0.01% | 916 |
|
|
2016
Q1 | $4.66M | Buy |
56,470
+15,825
| +39% | +$1.29M | 0.02% | 585 |
|
|
2015
Q4 | $4.26M | Sell |
40,645
-89,821
| -69% | -$9.38M | 0.02% | 499 |
|
|
2015
Q3 | $13.7M | Buy |
130,466
+20,524
| +19% | +$2.74M | 0.03% | 332 |
|
|
2015
Q2 | $15M | Sell |
109,942
-32,348
| -23% | -$4.01M | 0.04% | 244 |
|
|
2015
Q1 | $17.7M | Buy |
142,290
+136,334
| +2,289% | +$14.4M | 0.05% | 246 |
|
|
2014
Q4 | $538K | Sell |
5,956
-2,344
| -28% | -$195K | ﹤0.01% | 1104 |
|
|
2014
Q3 | $599K | Sell |
8,300
-2,316
| -22% | -$152K | ﹤0.01% | 1455 |
|
|
2014
Q2 | $660K | Sell |
10,616
-2,931,071
| -100% | -$177M | ﹤0.01% | 1366 |
|
|
2014
Q1 | $302M | Buy |
2,941,687
+2,928,798
| +22,723% | +$216M | 0.23% | 67 |
|
|
2013
Q4 | $906K | Sell |
12,889
-26,057
| -67% | -$1.77M | ﹤0.01% | 1090 |
|
|
2013
Q3 | $2.81M | Buy |
38,946
+25,116
| +182% | +$1.67M | ﹤0.01% | 841 |
|
|
2013
Q2 | $772K | Buy |
+13,830
| New | +$862K | ﹤0.01% | 1193 |
|
Other funds holding BMRN
VPC
BNP Paribas Financial Markets's BMRN Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its BioMarin Pharmaceuticals (BMRN) stake by 9.2% in Q2 2026, buying an estimated $2.27M and bringing the position to 490,189 shares worth $28M. The position accounts for 0.01% of the portfolio, ranked #1063.
BNP Paribas Financial Markets first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $302M in Q1 2014. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- BNP Paribas Financial Markets held 490,189 shares of BioMarin Pharmaceuticals worth $28M as of Q2 2026.
- BNP Paribas Financial Markets bought 41,421 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
- BioMarin Pharmaceuticals made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1063 holding.
- BNP Paribas Financial Markets first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- BNP Paribas Financial Markets's BioMarin Pharmaceuticals position peaked at $302M in Q1 2014.
- 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.